PORTOLA PHARMACEUTICALS INC
PTLA evidence brief
What we can confirm
- BioSniper Score:
- 8.6 / 10
- Lead Asset:
- andexxa (Approved)
What it means
What to watch
Prepared research question
What matters most for PTLA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
andexxa (Approved)
Next Catalyst
—
Tracking 4 pipeline candidates · 4 clinical trials · 1 FDA decision for PORTOLA PHARMACEUTICALS INC.
Run PORTOLA PHARMACEUTICALS INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available PORTOLA PHARMACEUTICALS INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Approved
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Governance
Frequently asked questions
What is PORTOLA PHARMACEUTICALS INC's lead drug candidate?
PORTOLA PHARMACEUTICALS INC's most advanced tracked candidate is andexxa (Approved) for reversal of anticoagulation in patients treated with rivaroxaban and apixaban when reversal is needed due to life-threatening or uncontrolled bleeding.
Who is the CEO of PORTOLA PHARMACEUTICALS INC?
Transition Committee is the chief executive officer of PORTOLA PHARMACEUTICALS INC (PTLA).
What therapeutic areas does PORTOLA PHARMACEUTICALS INC focus on?
PORTOLA PHARMACEUTICALS INC develops therapies across Oncology, Ophthalmology, Cardiovascular, Hematology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.